Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.04. | Apollomics tags out of TYG oncology pact to cut costs, extend runway into 2026 | 1 | FierceBiotech | ||
APOLLOMICS Aktie jetzt für 0€ handeln | |||||
03.04. | Apollomics Inc. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
03.04. | Apollomics GAAP EPS of -$52.80 | 2 | Seeking Alpha | ||
03.04. | Apollomics Inc.: Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress | 90 | GlobeNewswire (Europe) | Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew... ► Artikel lesen | |
01.04. | Apollomics and LaunXP agree on NSCLC treatment in Asia | 2 | Pharmaceutical Technology | ||
31.03. | Apollomics hands Asia rights to its lead c-MET inhibitor to Taiwan's LaunXP in $60M deal | 1 | FierceBiotech | ||
31.03. | Apollomics, LaunXP enter development, commercial agreement for Vebreltinib | 1 | Seeking Alpha | ||
31.03. | Apollomics Inc.: Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib | 1 | GlobeNewswire (USA) | ||
31.03. | Apollomics Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
20.12.24 | Apollomics Phase-3-Studie in China zeigt keine Vorteile | 1 | Investing.com Deutsch | ||
20.12.24 | Apollomics phase 3 trial in China shows no benefit | 1 | Investing.com | ||
20.12.24 | Apollomics Inc.: Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia | 248 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology... ► Artikel lesen | |
20.12.24 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
10.12.24 | Apollomics regains compliance with Nasdaq's minimum bid price requirement | 1 | Seeking Alpha | ||
10.12.24 | Apollomics Inc.: Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 105 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat... ► Artikel lesen | |
10.12.24 | Apollomics Inc. - 6-K, Report of foreign issuer | - | SEC Filings | ||
21.11.24 | Apollomics Inc.: Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split | 281 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology... ► Artikel lesen | |
14.08.24 | Apollomics Inc.: Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress | 142 | GlobeNewswire (Europe) | Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million... ► Artikel lesen | |
13.08.24 | Apollomics Inc.: Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial | 135 | GlobeNewswire (Europe) | FOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NANOREPRO | 1,675 | -1,18 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,437 | -2,02 % | NurExone stärkt US-Präsenz und bereitet klinische Studien vor | ||
REDHILL BIOPHARMA | 1,960 | +1,55 % | RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency | The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected... ► Artikel lesen | |
IBIO | 0,985 | +6,29 % | iBio, Inc.: iBio Reports Fiscal Third Quarter 2025 Financial Results | SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.... ► Artikel lesen | |
ARROWHEAD PHARMACEUTICALS | 14,850 | +0,75 % | Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" | ||
COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
CELLECTIS | 1,282 | +1,75 % | Cellectis Inc.: Monthly information on share capital and company voting rights | ||
VOYAGER THERAPEUTICS | 3,174 | +2,59 % | Voyager Therapeutics, Inc. - 8-K, Current Report |